优化正基KV7.2/3通道调节器,以改善脂性和水溶性平衡
Jana Lemke1, Nadine Mengers1, Louis Schmidt1
1Institute of Pharmacy, University of Greifswald, Friedrich-Ludwig-Jahn-Str. 17, Greifswald 17489, Germany.
Journal of medicinal chemistry
|April 8, 2025
概括
研究人员优化了KV7.2/3通道激活器,提高了溶解度20倍,同时保持了高功效. 这解决了开发针对这些重要的通道的新药的主要挑战.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 电压通道KV7.2/3与各种疾病有关.
- 现有的KV7.2/3激活剂已从市场上撤回.
- 针对KV7.2/3的强效化合物往往表现出不良的物理化学特性,阻碍了药物开发.
研究的目的:
- 为了优化KV7.2/3通道激活器的物理化学特性.
- 为了提高水溶性,同时保持对潜在药物候选物的高强度.
- 为了增强药物类特征以准与膜结合的离子通道.
主要方法:
- 合成和选42种针对KV7.2/3通道的新型化合物.
- 对化合物的活性 (pEC50) 和水溶性 (S) 的评估.
- 结构-活动关系 (SAR) 分析和计算建模以了解物业改进.
主要成果:
- 在42种合成的化合物中,有30种在KV7.2/3通道上表现出活性.
- 15种化合物与最初的打击化合物相比,具有更好的可溶性.
- 化合物实现了20倍的可溶性增加 (21.7微米对1.1微米),但功效仅略有下降 (pEC50 = 7.42对7.96).
- 结构修改导致可溶性增强和膜保留减少,理论上改善了目标接触.
结论:
- 成功的优化导致了KV7.2/3激活剂,具有显著改善的溶解性和类似药物的特性.
- 优化的化合物代表了进一步开发治疗与KV7.2/3通道功能障碍相关的条件的有希望的候选人.
- 平衡脂性,活性和可溶性对于开发有效的通道调节器至关重要.
相关概念视频
Allosteric Regulation
57.2K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.2K
Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K
Cooperative Allosteric Transitions
7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K
Drug Discovery: Overview
7.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.2K
The Two-State Receptor Model
1.8K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.8K
Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K


